𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A148: A Multi-Center, Double-Blind, Randomized-Withdrawal Trial of Subcutaneous Golimumab in Pediatric Patients With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy: Week 48 Results

✍ Scribed by Brunner, Hermine; Ruperto, N.; Tzaribachev, N.; Horneff, G.; Wouters, C.; Panaviene, V.; Chasnyk, V.; Abud-Mendoza, C.; Cuttica, R.; Reiff, A.; Maldonado-Velázquez, M.; Rubio-Perez, N.; Alexeeva, Ekaterina; Joos, R.; Keltsev, V.; Nasonov, E.; Kingsbury, D.; Bandeira, M.; Silverman, E.; Weller-Heinemann, F.; van Royen-Kerkhof, A.; Mendelsohn, Alan; Kim, Lilianne; Lovell, D.; Martini, A.

Book ID
121741862
Publisher
Wiley (John Wiley & Sons)
Year
2014
Tongue
English
Weight
53 KB
Volume
66
Category
Article
ISSN
2326-5191

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Golimumab, a human anti–tumor necrosis f
Golimumab, a human anti–tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four–week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis
✍ Paul Emery; Roy M. Fleischmann; Larry W. Moreland; Elizabeth C. Hsia; Ingrid Str 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 135 KB 👁 1 views
Erratum: Golimumab, a human anti-tumor n
Erratum: Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis
✍ Paul Emery; Roy M. Fleischmann; Larry W. Moreland; Elizabeth C. Hsia; Ingrid Str 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 38 KB 👁 1 views